Primary tumor cells obtained from MNU-induced mammary carcinomas show immune heterogeneity which can be modulated by low-efficiency transfection of CD40L gene

Cancer Biology and Therapy

Volumn 8, Issue 2, 2009, Pages 136-142

  Esendagli, Gunes ^a   Canpinar, Hande ^a   Yilmaz, Guldal ^b,d   Gunel Ozcan, Aysen ^a,c   Guc, M Oguz ^a   Kansu, Emin ^a   Guc, Dicle ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c KIRIKKALE UNIVERSITY   (Turkey)

^d GAZI UNIVERSITY   (Turkey)

Author keywords

CD40; CD40 ligand; Immune heterogeneity; Mammary cancer; Primary cell culture; Transfection

Indexed keywords

CD40 LIGAND; CXCL1 CHEMOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHYLNITROSOUREA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIMARY TUMOR; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

EID: 58749106788     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.2.7078     Document Type: Article

References (36)

1. Parkin M, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 2007; 7:791-9.
3. Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 2004; 16:143-50.
4. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, Zwieten MJ. Comparative study of human and rat mammary tumorigenesis. Lab Invest 1990; 62:244-78.
5. Singh M, McGinley JN, Thompson HJ. A comparison of the histopathology of premalignant and malignant mammary gland lesions induced in sexually immature rats with those occuring in the human. Lab Invest 2000; 80:221-31.
6. Roomi MW, Roomi NW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. Modulation of N-methyl-N-nitrosourea induced mammary tumors in Sprague-Dawley rats by combination of lysine, proline, arginine, ascorbic acid and green tea extract. Breast Cancer Res 2005; 7:291-5.
7. Thompson H, McGinley J, Wolfe P, Singh M, Steele V, Kelloff G. Temporal sequence of mammary intraductal proliferations, ductal carcinomas in situ and adenocarcinomas induced by 1-methyl-1-nitrosourea in rats. Carcinogenesis 1998; 19:2181-5.
8. Manickasingham S, Sousa CR. Microbial and T Cell-derived stimuli regulate antigen presentation by dendritic cells in vivo. J Immunol 2000; 165:5027-34.
9. Costello RT, Gastaut J-A, Olive D. What is the role of CD40 in cancer immunotherapy? Immunol Today 1999; 20:488-93.
10. Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM, Stone MJ. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 2001; 7:691-703.
11. Hirano A, Longo DL, Taub DD, Ferris DK, Young LS, Eliopoulos AG, Agathanggelou A, Cullen N, Macartney J, Fanslow WC, Murphy WJ. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999; 93:2999-3007.
12. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW. CD40 and epithelial cells: across the great divide. Immunol Today 1998; 19:502-6.
13. Gahamande S, Hylander BL, Oflazoglu E, Lele S, Fanslow WC, Repasky EA. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 2001; 61:7556-62.
14. Tatay-Moret I, Diaz J, Marco FM, Crespo A, Alino SF. Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors. Cancer Gene Ther 2003; 10:887-97.
15. Couderc B, Zitvogel L, Douin-Echinard V, Djennane L, Tahara H, Favre G, Lotze MT, Robbins PD. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) and CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther 1998; 5:163-75.
16. Grangeon C, Cormary C, Douin-Echinard V, Favre G, Couderc B, Mariame-Tilkin A-F. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells. Cancer Gene Ther 2002; 9:282-8.
17. Cohen LA. Isolation and characterization of a serially cultivated, neoplastic, epithelial cell line from the N-nitrosomethylurea induced rat mammary adenocarcinoma. In Vitro 1982; 18:565-75.
18. Freshney RI, Freshney MG. Culture of specialized cells - Culture of epithelial cells. New York, USA: Wiley-Liss Inc 2002.
19. Esendagli G, Gunel-Ozcan A, Canpinar H, Guc D. Molecular and functional analysis of a novel recombinant clone of rat (Rattus norvegicus) CD40 ligand (CD40L) gene. Mol Biol Rep 2007; in press.
20. Trinite B, Voisine C, Yagita H, Josien R. A subset of cytolytic dendritic cells in rat. J Immunol 2000; 165:4202-8.
21. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:45.
22. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999; 11:263-70.
23. Tanswell AK, Staub O, Iles R, Belcastro R, Cabacungan J, Sedlackova L, Steer B, Wen Y, Hu J, O'brodovich H. Liposome-mediated transfection of fetal epithelial cells: DNA degradation and enhanced superoxide toxicity. Am J Physiol 1998; 275:452-60.
24. Banat G-A, Christ O, Cochlovius B, Pralle HB, Zöller M. Tumor-induced suppression of immune response and its correction. Cancer Immunol Immunother 2001; 49:573-86.
25. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Immunol 2007; 7:659-72.
26. Wingett DG, Vestal RE, Forcier K, Hadjokas N, Nielson CP. CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat 1998; 50:27-36.
27. Basolo F, Conaldi PG, Fiore L, Calvo S, Toniolo A. Normal breast epithelial cells produce interleukins 6 and 8 together with tumor-necrosis factor: defective IL-6 expression in mammary carcinoma. Int J Cancer 1993; 55:926-30.
28. Varela LM, Stangle-Castor NC, Shoemaker SF, Shea-Eaton WK, Ip MM. TNFalpha induces NFκB/p50 in association with the growth and morphogenesis of normal and transformed rat mammary epithelial cells. J Cell Physiol 2001; 188:120-31.
29. Liu L, Gudas LJ. Retinoic acid induces expression of the interleukin-1b gene in cultured normal human mammary epithelial cells and in human breast carcinoma lines. J Cell Physiol 2002; 193:244-52.
30. Brown BD, Lillicrap D. Dangerous liaisions: the role of "danger" signals in the immune response to gene therapy. Blood 2002; 100:1133-40.
31. Matzinger P. The Danger Model: A renewed sense of self. Science 2002; 296:301-5.
32. Alexandroff AB, Jackson AM, Paterson T, Haley JL, Ross JA, Longo DL, Murphy WJ, James K, Taub DD. Role for CD40-CD40 ligand interactions in the immune response to solid tumors. Mol Immunol 2000; 37:515-26.
33. Perez-Melgosa M, Hollenbaugh D, Wilson CB. Cutting edge: CD40 ligand is a limiting factor in the humoral response to T cell-dependent antigens. J Immunol 1999; 163:1123-7.
34. Abbas AK, Lichtman AH, Pober JS. Cellular and Molecular Immunology. Philadelphia, USA: WB Saunders Co 2003.
35. Makrigiannis AP, Musgrave BL, Hoskin DW. Differential effects of B7-1 and B7-2 on the costimulation of mouse nonspecific cytotoxic T lymphocyte development in response to anti-CD3 antibody. J Leukoc Biol 1999; 66:792-802.
36. Peggs KS, Allison JP. Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. Br J Haematol 2005; 130:809-24.